Background: In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators.
Commentary: This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions.
Conclusion: This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15563650.2023.2182664 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!